You are here

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Combination immunotherapies
440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2024

AbstractFullPdf
Nov 2020133010
Dec 202084011
Jan 20212808
Feb 20211806
Mar 20215208
Apr 20211007
May 20211011
Jun 2021004
Jul 2021002
Aug 2021006
Sep 2021008
Oct 202124022
Nov 202142020
Dec 202132014
Jan 20226407
Feb 20221907
Mar 202224010
Apr 202242010
May 20222000
Jun 20223002
Jul 20221202
Aug 202230010
Sep 20222206
Oct 20222601
Nov 20223402
Dec 202252010
Jan 20231801
Feb 20233003
Mar 20232804
Apr 20233002
May 20232402
Jun 20233003
Jul 20233402
Aug 20232400
Sep 20232302
Oct 20232402
Nov 20234805
Dec 20235602
Jan 20244202
Feb 20242201
Mar 20242202
Apr 20242201
May 20242804
Jun 20242201
Jul 20243601
Aug 20243001
Total13920245